St. Louis (September 29, 2020) – Intalere, the healthcare industry leader in delivering solutions designed for improved financial, operational and clinical health for our partners, announces a new agreement with Tetraphase Pharmaceuticals, Inc.

Through this agreement Intalere members will receive negotiated pricing on Tetraphase branded novel antibiotics including XERAVA™, approved for the treatment of complicated intra-abdominal infections (cIAI). Tetraphase is tackling the challenging clinical threat presented by antimicrobial resistance by developing new antibiotics that can overcome the challenges of drug-resistant bacteria and ensure the availability of effective treatments in the future.

This contract is currently effective through December 31, 2021.


About Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention. Tetraphase has created more than 3,000 novel tetracycline compounds using its proprietary technology platform. Tetraphase's lead product, XERAVA™, is approved for the treatment of complicated intra-abdominal infections by the U.S. Food and Drug Administration and the European Commission. Tetraphase’s pipeline also includes antibiotics TP-271 and TP-6076, which are Phase 2 ready, and TP 2846, which is in preclinical testing for acute myeloid leukemia. Tetraphase intends to out license its pipeline candidates.


About Intalere
Intalere’s mission focuses on elevating the health of healthcare by designing solutions to improve our members’ financial, operational and clinical performance. We empower our customers and deliver measurable results through our highly personalized approach of creating strategies and programs focused on their goals. From managing their entire spend to strategic consulting around diagnosing particular areas of concern, our unique provider led model allows us to leverage nationally recognized best practices in supply chain and patient outcomes to drive efficiencies for our members.